About Ginkgo Bioworks
Ginkgo Bioworks (NYSE: DNA) provides biotechnology solutions. It offers enzyme services, protein services, metabolic engineering services, strain optimization services, biosecurity services, and more. It serves a wide range of industries including biopharmaceuticals, cosmetics, nutrition, food, agriculture, medicine, industrial, government, and more. The company was founded in 2009 and is based in Boston, Massachusetts.
Research containing Ginkgo Bioworks
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Ginkgo Bioworks in 5 CB Insights research briefs, most recently on Dec 2, 2022.
Expert Collections containing Ginkgo Bioworks
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Ginkgo Bioworks is included in 3 Expert Collections, including Synthetic Biology.
Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.
Drug Discovery Tech Market Map
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Food & Beverage
Ginkgo Bioworks Patents
Ginkgo Bioworks has filed 53 patents.
Proteins, Molecular biology, Units of information, Bacillales, Bacteriology
Proteins, Molecular biology, Units of information, Bacillales, Bacteriology
Latest Ginkgo Bioworks News
Sep 21, 2023
Cambridge, Massachusetts, UNITED STATES CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced its management team will participate in Chardan’s 7th Annual Genetic Medicines Conference, being held in New York, October 2-3, 2023. In addition to one-on-one meetings with investors, Synlogic CEO Dr. Aoife Brennan will participate in a Fireside Chat on Monday, October 2 at 4:30 p.m. Eastern Time. A live webcast of the fireside chat will be available in the investor section of the company's website at www.synlogictx.com , and will be available for replay after the conference. To register for the conference or request one-on-one meetings, please contact your Chardan representative. About Synlogic Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options. The Company’s late-stage pipeline is focused on rare metabolic diseases, led by labafenogene marselecobac (SYNB1934), currently being studied as a potential treatment for phenylketonuria (PKU) in Synpheny-3, a global, pivotal Phase 3 study. Additional product candidates address diseases including homocystinuria (HCU), enteric hyperoxaluria, gout, and cystinuria. This pipeline is fueled by the Synthetic Biotic platform, which applies precision genetic engineering to well-characterized probiotics. This enables Synlogic to create GI-restricted, oral medicines designed to consume or modify disease-specific metabolites – an approach well suited for PKU and HCU, both inborn errors of metabolism, as well as other disorders in which the disease–specific metabolites transit through the GI tract, providing validated targets for these Synthetic Biotics. Research activities include a partnership with Roche focused on inflammatory bowel disease (IBD), and a collaboration with Ginkgo Bioworks in synthetic biology, which has contributed to two pipeline programs to date. For more information, please visit www.synlogictx.com or follow us on Twitter , LinkedIn , Facebook or Instagram . This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "look forward, " "estimate," "expect," "intend," "on track, " "plan," "predict" and similar expressions and their variants, as they relate to Synlogic, may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's approach to Synthetic Biotics to develop therapeutics to address a wide range of diseases including: inborn errors of metabolism and inflammatory and immune disorders; our expectations about sufficiency of our existing cash balance; the future clinical development of Synthetic Biotics; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; and the expected timing of Synlogic's clinical trials of labafenogene marselecobac (SYNB1934), SYNB1353, SYNB8802 and SYNB2081 and availability of clinical trial data. Actual results could differ materially from those contained in any forward-looking statements as a result of various factors, including: the uncertainties inherent in the clinical and preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" in Synlogic's filings with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Synlogic's current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.
Ginkgo Bioworks Frequently Asked Questions (FAQ)
When was Ginkgo Bioworks founded?
Ginkgo Bioworks was founded in 2009.
Where is Ginkgo Bioworks's headquarters?
Ginkgo Bioworks's headquarters is located at 27 Drydock Avenue, Boston.
What is Ginkgo Bioworks's latest funding round?
Ginkgo Bioworks's latest funding round is PIPE.
How much did Ginkgo Bioworks raise?
Ginkgo Bioworks raised a total of $796.25M.
Who are the investors of Ginkgo Bioworks?
Investors of Ginkgo Bioworks include Baillie Gifford & Co., Soaring Eagle Acquisition, National Institutes of Health, Viking Global Investors, General Atlantic and 21 more.
Who are Ginkgo Bioworks's competitors?
Competitors of Ginkgo Bioworks include Allozymes, Algal Bio, EnginZyme, Biosyntia, Biosortia Microbiomics and 7 more.
Compare Ginkgo Bioworks to Competitors
Verily Life Sciences develops tools and devices to collect, organize and activate health data, and creates interventions to prevent and manage the disease. It partners with leading life sciences, medical devices, and government organizations, using deep hardware, software, scientific, and healthcare expertise to enable faster development, meaningful advances, and deployment at scale. The company was founded in 2015 and is based in South San Francisco, California.
Epic specializes in the development of software for healthcare organizations.
Embr Labs is a thermal wellness technology company that develops a wristband that uses temperature to activate and balance the body and mind. It leverages the body and mind's natural response to temperature to help people feel comfortable, fall asleep, and manage stress. The company was founded in 2014 and is based in Boston, Massachusetts.
Koda Health develops a data-driven, personalized, interactive, and video-based platform to navigate end-of-life conversations. The company offers advanced care planning for accountable care organizations, value-based care, health plans, hospital systems, and more. It was founded in 2020 and is based in Houston, Texas.
PointClickCare helps care providers to connect, collaborate, and share data within their network. PointClickCare provides diverse care teams across the care continuum with real‐time patient insights at any stage of a patient’s healthcare journey, enabling better decision-making and improved clinical outcomes at a lower cost.
Very Good Security (VGS) operates as a data security platform. The company's platform offers protection services to secure payments, medical records, communication, and secure forms by keeping the data safe without making any changes in the system. It was founded in 2015 and is based in San Francisco, California.